|
Phage Display |
Yeast Display |
Ribosome and Puromycin Display |
DNA or RNA Aptamers |
Animals |
|
|---|---|---|---|---|---|
|
Strengths |
Good diversity Fusion proteins |
Liquid and fluorescence-based screening Affinity maturation Fusion proteins |
Good diversity Fusion proteins |
Good diversity |
Many secondary antibodies available |
|
Weaknesses |
Slower screening Plate based |
Fluorescent tags required that may complicate recognition Reduced cys on targets problematic |
Slower screening |
Fewer secondary affinity labels Not protein based, so no fusion proteins |
Expensive Not high throughput Nonrenewable unless use mAb Slow |
|
Development Targets and Needs |
High throughput demonstrated Improved screening |
High throughput Improved screening Secondary antibodies that must be developed |
Optimization of scaffolds, screening methods, and automation |
Optimization of screening methods |
Optimization of screen methodologies DNA immunization and improvements in hybridoma production |
June 14-16, 2004, GTL Technology Deep Dive Workshop, Working Group on Genome-Based Reagents
The table above compares and contrasts strengths, weaknesses, and development needs of technologies for use in a high-throughput production environment.